Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A UCLA-led study found that a combination of pembrolizumab and SD-101 can alter the tumor microenvironment, enabling the immune system to attack cancer more effectively. The treatment has shown promise in people receiving immunotherapy for the first time, with some patients experiencing complete tumor disappearance.
Research from the University of Sydney shows that high-quality medication reminder apps increase people's adherence to cardiovascular medication. A clinical trial found no additional benefits from advanced features like snooze reminders and social support structures.
Researchers at Hebrew University of Jerusalem have developed a new biological drug that has shown a 50% cure rate in lab mice with acute leukemia. The single-molecule drug targets multiple leukemic proteins, making it difficult for cancer cells to evade therapy and reducing the need for multiple treatments.
University of Bristol researchers have discovered a way to exploit hypoxia to kill cancer cells without harming healthy tissue. The study found that a specific receptor, GPRC5A, can be targeted using genetic techniques to trigger cancer cell death.
Scientists have created a more complete humanized mouse model by combining human hematopoietic stem and progenitor cells with mesenchymal stem cells. This allows for more realistic testing of immunotherapies, leading to improved cancer treatment predictions. The new model enables researchers to compare the interaction of the immune sys...
A new cancer drug lead, C1, has shown promise in reducing tumor size by forcing tumors back to normal metabolism. The approach combines two existing drugs, doxorubicin and dichloroacetic acid, to deliver a potent toxin and prevent tumor growth.
Researchers have developed a new class of anti-cancer medicines based on nanoMIPs, which selectively bind to specific molecular targets. This approach ensures high specificity and stability over temperature and acidity, expanding treatment options for various diseases.
Effective medical treatment and surgery prevent esophageal cancer in people with severe heartburn. The study used health data from 1964 to 2014 and found a significant decrease in cancer risk after treatment.
Researchers have developed a new drug that targets EBV-positive tumors and inhibits tumor development and metastases for EBV-related lymphomas. The findings suggest the drug may be useful in treating malignancies in EBV-positive patients.
Scientists at Salk Institute and Purdue University discovered a key to mass-producing beneficial plant compounds, including terpenoids used in fragrances, flavorings, biofuels, and pharmaceuticals. They found that plants have an
The new ESCAT grading system helps distinguish between tumour DNA alterations relevant for targeted medicine decisions and those that aren't. The system enables clinicians to prioritize mutations and make data-driven treatment choices.
Researchers create universal platform using magnetite-gold particles for targeted cancer treatments and simultaneous diagnosis. The breakthrough discovery enables therapeutic delivery of drugs to tumor cells while detecting them with magnetic resonance imaging.
A phase 1 clinical trial at the University of Colorado Cancer Center has shown promising results, with 72% 2-year survival in heavy smokers. The combination of olaparib, cetuximab, and radiation was found to be synthetically lethal for cancer cells, leading to enhanced cell death.
Researchers at Washington State University discovered that cancer-fighting drugs can slow or stop fungal infections in plants by activating genes used to defend against pathogens. The study showed two different results from the applications of DNA-specific drugs on pea tissue, with differing mechanisms of action.
Scientists have created specialized delivery methods using nucleic acid-based nanostructures to target cancer cells while leaving normal cells intact. The new approach utilizes aptamers to bind to specific receptors on cancer cells, allowing for the targeted delivery of chemotherapeutic drugs.
A novel approach targeting the RAS / MAP Kinase pathway slows cancer growth in lung, skin, colon, and pancreatic cancers. Researchers have identified a compound that effectively decouples the entire pathway from external growth signals, leading to significant inhibition of cancer growth.
Researchers at Penn Medicine discovered PARP inhibitors could prevent toxic TDP-43 accumulations in brain cells. The treatment shows promise for neurodegenerative disorders like ALS and FTD.
A new cancer therapy using nanoparticles could deliver a double blow to cancer by making breast and prostate tumours more sensitive to chemotherapy, reducing toxicity risks. The therapy combines two approved drugs, docetaxel and fingolimod, targeting cancer cells with reduced side effects.
A new study suggests that cancer treatment should be viewed as a game where physicians can exploit their knowledge of the cancer's evolutionary dynamics to develop flexible strategic treatment plans. By continuously adjusting drugs and doses, physicians can delay or prevent cancer progression caused by resistance.
Researchers discovered a previously unrecognized mechanism by which arsenic trioxide and all-trans retinoic acid work together to destroy Pin1, a unique enzyme that activates over 40 cancer-driving proteins. This finding suggests novel strategies to treat common cancers, including triple-negative breast cancer.
Researchers identify MUC5AC gene as a key player in KRAS-mutant non-small cell lung cancers, which are resistant to current treatments. Inhibiting this gene may lead to new therapeutic strategies against KRAS-driven lung cancer.
Researchers at SwRI and UTSA are developing a biodegradable implant that can deliver personalized doses of medicine to treat various illnesses. The implant is designed to be drug agnostic and can work with any type of drug, potentially treating a wide range of diseases.
Nanoparticles have been modified to be absorbed through the lymphatic system, increasing bioavailability seven-fold. The new technique uses glycocholic acid as a cloak to help nanoparticles slip incognito through the small intestine lining.
A new RNA sequencing platform has been developed to match thousands of drugs with late-stage and drug-resistant multiple myeloma patients, providing a more accurate treatment approach. The platform's results showed that a majority of patients benefited from personalized treatment plans based on their cancer's RNA profile.
Researchers developed a new sensor that detects hydrogen peroxide levels in human cells to identify effective chemotherapy drugs. The sensor can be used to screen existing drugs and predict success in individual patients' tumors. This breakthrough could lead to more targeted and effective cancer treatments.
A new method has been developed to deliver curcumin to cancer cells, enhancing its effectiveness in treating various cancer types. The approach involves creating a sophisticated metallocyclic complex using platinum that increases curcumin's solubility and synergy.
A research team has developed a novel peptide drug called FFW that shows promise in reducing tumour growth and slowing down the spread of cancer cells. The drug targets SALL4 protein interactions, previously considered undruggable, and has shown effective results in lab experiments.
Researchers found that thalidomide acts by promoting the degradation of transcription factors, including SALL4, leading to limb and fetal growth complications. The study's findings will help guide development of new anticancer drugs with a similar scaffold.
Researchers have discovered a novel way to enhance targeted cancer drugs by testing cocktail combinations on human cancer cell lines, fruit flies, and mice. The findings suggest that these cocktail combinations can be used with targeted therapy drugs or after failed attempts.
Senescent cells, also known as 'zombie cells,' interfere with tissue function and contribute to aging diseases. Researchers have designed a nano-carrier that selectively targets these cells, releasing drugs to kill them and improving therapeutic outcomes in pulmonary fibrosis and cancer models.
Researchers discovered a new lead compound that could improve existing treatments for cancer, diabetes and obesity. The study identified the HDAC11 enzyme as a crucial target for developing new drugs.
Researchers at the Weizmann Institute of Science have developed a new combination therapy using three drugs to block growth from without and within, potentially relieving resistance in lung cancer patients. The approach was successful in mice and may help extend the lives of thousands of lung cancer patients.
Researchers identified Shieldin, a protein complex that regulates DNA repair and may explain why some patients develop resistance to new anti-cancer drugs. The study's findings suggest that Shieldin levels can be used as a marker for identifying patients likely to respond poorly to PARP inhibitors.
Researchers found that patients using complementary medicine had a higher risk of death and were more likely to refuse conventional cancer treatments. The study analyzed data from over 1,290 patients with breast, prostate, lung, or colorectal cancer.
A team of researchers has uncovered a new protein complex called Shieldin that plays a critical role in normal cell division and cancer treatment. The complex shields broken DNA ends and controls the type of DNA repair system used by cells, making it vulnerable to targeting by PARP inhibitors and platinum-based chemotherapies.
A review of cannabinoids suggests they can stop cancer cells from dividing and invading normal tissue. Cannabinoids may also enhance the immune response against tumor growth and spread, providing potential new treatment options for cancer patients.
Leukemia cells infiltrate the central nervous system by grabbing onto laminin proteins and zipping down into the meninges region where cerebral spinal fluid circulates. This discovery arms researchers with new ways to target this pathway and potentially shut it down.
Researchers at Dana-Farber Cancer Institute found biomarkers in melanoma that can help tailor immunotherapy treatments. The study suggests that some patients with advanced melanoma may not benefit from combination therapy, but could do well with single-agent treatment.
Researchers investigating genetic and environmental factors contributing to aggressive prostate cancer in African-American men, a population with a 15% lifetime risk compared to 10% for white men.
The RESPOND study, funded by $26.5 million grants, aims to understand why African-American men are at higher risk for developing aggressive forms of prostate cancer. Researchers will assess social stressors and genetics to identify genetic markers for the disease.
A team of international researchers has mapped the family trees of cancer cells in AML to understand its response to enasidenib and how it can be combined with other anti-cancer drugs. The study provides clues about how AML cells become resistant to therapy and may help design future therapy trials.
Yale Cancer Center scientists have found that rare inherited cancer syndromes are driven by a breakdown in how cells repair their DNA. They suggest using PARP inhibitors to treat these conditions.
Researchers found that omega-3 fatty acid metabolites, called endocannabinoids, can slow tumor growth and inhibit cancer cell migration in mice with osteosarcoma. These molecules were also shown to kill cancer cells, but not as effectively as other chemotherapeutic drugs.
Researchers developed a method to create 3D cultures of clustered cancer cells that better mimic tumors, enabling more accurate drug testing. A new NIH grant will model the response of colon cancer cells to anticancer drugs, aiming to identify molecular mechanisms of drug resistance and develop new treatment strategies.
Researchers developed a technique to measure drug-target engagement in individual cancer cells, revealing variation in effectiveness between cells within a tumour. The findings could help clinicians choose the best course and delivery of treatment for cancer patients, improving treatment outcomes.
Researchers at the University of Zurich have developed a new method to quickly test various anti-cancer drugs and treatment combinations at the cellular level. The approach has revealed how PARP inhibitors work in cancer cells by locking their target protein in an inactive state, leading to DNA damage and cell death.
A University of Colorado Cancer Center study found that brain metastases are a common occurrence in stage IV ROS1-positive non-small cell lung cancer. The study also showed that patients with ROS1 mutations had similar progression-free survival rates as ALK patients when treated with crizotinib, but with a higher risk of brain metastas...
A Phase 1b clinical trial has demonstrated that the combination of tucatinib and T-DM1 can control median 8.2 months in heavily pretreated HER2-positive breast cancer patients, with 48% response rate. The drug also shows efficacy against brain metastases, a major cause of mortality from the disease.
A new UK-based institute at the University of Cambridge is using cutting-edge analytics to maximize the use of big data sets in cancer patient care. The Mark Foundation Institute for Integrated Cancer Medicine aims to integrate clinical, genomic, and image data to inform treatment decisions.
A team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML) by identifying genetic mutations in their blood. By analyzing data from a large population health study, the researchers found that people with early mutations are more likely to develop AML.
Researchers reveal curcumin binds to and inhibits DYRK2, impairing cell proliferation and reducing cancer burden. Curcumin's effectiveness may be limited due to its rapid expulsion from the body.
Researchers have identified a new target for treating certain types of leukemia by exploiting an existing FDA-approved drug, Ibrutinib. This discovery could provide another treatment option for patients and accelerate clinical trials.
A cost-effectiveness study analyzed risk-based breast cancer screening programs versus standard age-based screening, evaluating their impact on healthcare resources and patient outcomes. The study found that risk-based screening programs can be more cost-effective than traditional age-based programs for certain populations in the UK.
Researchers have found that cancer stem cells exist in multiple states and can change form, making them resistant to treatment. By targeting cell metabolism, they may be able to kill these stem cells, potentially opening up a new approach to cancer therapy.
A new computer algorithm developed by Johns Hopkins researchers can predict when cancer cells will develop resistance to treatment. The Coordinate Gene Activity in Pattern Sets (CoGAPS) algorithm uses in vitro cell models and computational analysis to track molecular changes over time.
Researchers at Brigham and Women's Hospital have developed a supramolecular therapeutic that blocks the 'eat me not' signal sent by cancer cells and converts macrophages to the attacking M1 subtype. The approach has yielded promising results in preclinical models, showing complete inhibition of tumor growth and increased survival rates.
Scientists at Scripps Research found that several existing FDA-approved anti-cancer drugs bind tightly to RNA, modulating targets and causing some effects. The discovery offers a promising new approach for tackling diseases considered undruggable, including ALS and certain cancers.
A new study finds that enzalutamide significantly lowers the risk of metastasis or death in men with non-metastatic castrate-resistant prostate cancer, delaying cancer re-appearance by almost two years. The drug also shows a 71% lower risk of metastasis or death compared to placebo.
Researchers discovered a molecular inhibitor that could help fight prostate cancer when resistance develops to CDK4/6 inhibitors. The study found that tumors become more aggressive and dependent on the MAPK-6 pathway when resistance occurs, making MEK inhibitors a potential therapeutic option.
A new study found that an experimental drug called AZ32 selectively sensitizes brain tumors to radiation, extending the survival of mouse models with human glioblastoma multiforme. The combination therapy forced GBM cells to undergo mitotic catastrophe, leading to cell death.